Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trialChristopher J. Sweeney, Anthony Dowling, M. C. George et al.|The Lancet Oncology|2023Cited by 195
Multi-Arm GlioblastoMa Australasia (MAGMA): protocol for a multiarm randomised clinical trial for people affected by glioblastomaBenjamin Y. Kong, Craig Gedye, Hao‐Wen Sim et al.|BMJ Open|2022Cited by 7
Beyond standard data collection – the promise and potential of BRAIN (Brain tumour Registry Australia INnovation and translation registry)Lucy Gately, Peter Gibbs, Katharine J. Drummond et al.|BMC Cancer|2022Cited by 7
A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastomaLucy Gately, Carmen Balañá, Carlos Mesía et al.|Journal of Neuro-Oncology|2023Cited by 5
Correction to: A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastomaLucy Gately, Carmen Balañá, Carlos Mesía et al.|Journal of Neuro-Oncology|2024Cited by 3